NYSE - Nasdaq Real Time Price USD

Enzo Biochem, Inc. (ENZ)

0.3138

-0.0678

(-17.77%)

As of April 17 at 4:00:02 PM EDT. Market Open.

Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction

Forms Special Committee of the Board to Lead Evaluation of Viable Options for Maximizing Shareholder Value Engages Independent Financial and Legal Advisors to Support Thorough Process Remains Committed to Maintaining Focus on Cost Containment, Cash Preservation and Near-Term Initiatives to Enhance Value Farmingdale, NY, April 22, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (OTCQX: ENZB) (“Enzo” or the “Company”) today announced that its Board of Directors (the “Board”) has commenced a review of

GlobeNewswire 2 days ago

ENZ
-17.77%
ENZB
The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment

AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment are included in this Analyst Blog.

Zacks 8 days ago

ABBV

ENZ
-17.77%
CVV
Top Research Reports for AbbVie, TJX & Charles Schwab

Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), The TJX Companies, Inc. (TJX) and The Charles Schwab Corporation (SCHW), as well as two micro-cap stocks, Enzo Biochem, Inc. (ENZ) and CVD Equipment Corporation (CVV).

Zacks 8 days ago

ABBV

SCHW

TJX
Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX

FARMINGDALE, N.Y., March 28, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced its intention to voluntarily delist its common stock from The New York Stock Exchange (“NYSE”) and to have its common stock quoted on the OTCQX Best Market (“OTCQX”). Enzo provided notice of the voluntary delisting to the NYSE on March 28, 2025 and intends to timely file a notification of removal from listing on Form 25 with the Securities and Exchange Commission (the “S

GlobeNewswire 26 days ago

ENZ
-17.77%
Here’s Why Enzo Biochem (ENZ) Declined in Q4

Kingdom Capital Advisors, a private investment firm, released its fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here. Kingdom Capital Advisors is in its third year of operation as of the end of 2024. Since the firm’s inception, small cap stocks, as determined by the Russell 2000 TR, have experienced a […]

Insider Monkey last month

ENZ
-17.77%
ENZ Stock Down Following Q2 Earnings, Revenues Decline Y/Y

Enzo Biochem revenues decline in second-quarter fiscal 2025. Cost cuts improve margins, but NYSE compliance issues and market slowdown persist.

Zacks last month

ENZ
-17.77%
^GSPC
Enzo Biochem: Fiscal Q2 Earnings Snapshot

FARMINGDALE, N.Y. (AP) — Enzo Biochem Inc. ENZ) on Monday reported a loss of $1.5 million in its fiscal second quarter. The Farmingdale, New York-based company said it had a loss of 3 cents per share.

Associated Press Finance last month

ENZ
-17.77%
Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results

FARMINGDALE, N.Y., March 17, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal second quarter ended January 31, 2025, with sequential quarter improvement in revenue, gross margin and operating profit / loss. Financial Highlights The Company’s second-quarter gross margin percentage of 52% increased sequentially from 37% during Q1 2025 and increased from 49% during the second quarter of the prior year. These improveme

GlobeNewswire last month

ENZ
-17.77%
Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules

FARMINGDALE, N.Y, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced that it was notified by the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01B and Section 802.01C of the NYSE Listed Company Manual because (i) its 30 trading-day average market capitalization was less than $50 million and its last reported stockholder’s equity as of October 31, 2024 was less than $50 million and (ii) the average closin

GlobeNewswire 3 months ago

ENZ
-17.77%
ENZ Stock Falls Post Q1 Earnings Amid Revenue and Demand Challenges

Enzo Biochem reports a first-quarter fiscal 2025 quarterly loss and revenue drop across regions amid challenges in the life sciences tools market.

Zacks 4 months ago

ENZ
-17.77%
^GSPC
Enzo Biochem First Quarter 2025 Earnings: US$0.059 loss per share (vs US$0.11 loss in 1Q 2024)

Enzo Biochem ( NYSE:ENZ ) First Quarter 2025 Results Key Financial Results Revenue: US$6.21m (down 20% from 1Q 2024...

Simply Wall St. 4 months ago

ENZ
-17.77%
Enzo Biochem: Fiscal Q1 Earnings Snapshot

FARMINGDALE, N.Y. (AP) — Enzo Biochem Inc. ENZ) on Monday reported a loss of $3.4 million in its fiscal first quarter. On a per-share basis, the Farmingdale, New York-based company said it had a loss of 7 cents.

Associated Press Finance 4 months ago

ENZ
-17.77%
Enzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company Update

FARMINGDALE, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal first quarter ended October 31, 2024. First Quarter Highlights Enzo ended the first quarter with aggregate cash and cash equivalents of $47.7 million. The net cash used in operating activities during the first quarter decreased by $4.4 million compared to the prior year. The Company's first-quarter revenue of $6.2 million declined year-ove

GlobeNewswire 4 months ago

ENZ
-17.77%
The Zacks Analyst Blog Highlights Amgen, Eaton, Sony, iMage and Enzo Biochem

Amgen, Eaton, Sony, iMage and Enzo Biochem are included in this Analyst Blog.

Zacks 4 months ago

ETN

AMGN

ENZ
-17.77%
Top Stock Reports for Amgen, Eaton & Enzo Biochem

Today's Research Daily features new research reports on 16 major stocks, including Amgen Inc. (AMGN), Eaton Corp. plc (ETN) and Sony Group Corp. (SONY), as well as two micro-cap stocks, Moving iMage Technologies, Inc. (MITQ) and Enzo Biochem, Inc. (ENZ).

Zacks 4 months ago

AMGN

ENZ
-17.77%
ETN
US Penny Stocks To Watch In December 2024

As the U.S. market takes a breather from its post-election rally, major indices like the Dow Jones and S&P 500 are seeing slight declines while still riding high on recent record achievements. In this context, penny stocks—often smaller or newer companies—remain an intriguing investment area despite their somewhat outdated label. These stocks can offer unique growth opportunities, especially when backed by solid financials, making them worthy of attention for investors seeking under-the-radar...

Simply Wall St. 4 months ago

ENZ
-17.77%
ICAD

SYPR
We're Keeping An Eye On Enzo Biochem's (NYSE:ENZ) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 5 months ago

ENZ
-17.77%
Enzo Biochem Full Year 2024 Earnings: US$0.19 loss per share (vs US$0.51 loss in FY 2023)

Enzo Biochem ( NYSE:ENZ ) Full Year 2024 Results Key Financial Results Revenue: US$31.9m (up 2.7% from FY 2023). Net...

Simply Wall St. 5 months ago

ENZ
-17.77%
ENZ Stock Up Following FY24 Earnings Uptick, Gross Margin Expands

Enzo Biochem's overall topline benefits from revenue growth in the majority of its geographic regions.

Zacks 5 months ago

ENZ
-17.77%
Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend

FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company also announced that its board of directors had authorized a cash dividend of $0.10 per share of its common stock. Full Year Highlights The Company's revenues in the 2024 period of $31.9 million improved year-over-year by 3%. Enzo’s sales to its industri

GlobeNewswire 5 months ago

ENZ
-17.77%

Performance Overview

Return	ENZ	S&P 500 (^GSPC)
YTD	-56.07%	-6.80%
1-Year	-67.55%	+8.08%
3-Year	-87.72%	+28.32%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Enzo Biochem, Inc. (ENZ)

Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction

The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment

Top Research Reports for AbbVie, TJX & Charles Schwab

Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX

Here’s Why Enzo Biochem (ENZ) Declined in Q4

ENZ Stock Down Following Q2 Earnings, Revenues Decline Y/Y

Enzo Biochem: Fiscal Q2 Earnings Snapshot

Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results

Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules

ENZ Stock Falls Post Q1 Earnings Amid Revenue and Demand Challenges

Enzo Biochem First Quarter 2025 Earnings: US$0.059 loss per share (vs US$0.11 loss in 1Q 2024)

Enzo Biochem: Fiscal Q1 Earnings Snapshot

Enzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company Update

The Zacks Analyst Blog Highlights Amgen, Eaton, Sony, iMage and Enzo Biochem

Top Stock Reports for Amgen, Eaton & Enzo Biochem

US Penny Stocks To Watch In December 2024

We're Keeping An Eye On Enzo Biochem's (NYSE:ENZ) Cash Burn Rate

Enzo Biochem Full Year 2024 Earnings: US$0.19 loss per share (vs US$0.51 loss in FY 2023)

ENZ Stock Up Following FY24 Earnings Uptick, Gross Margin Expands

Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend

Performance Overview